112 related articles for article (PubMed ID: 11197074)
1. Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction.
Okabe H; Hashimoto Y; Inui KI
J Pharm Pharmacol; 2000 Dec; 52(12):1467-72. PubMed ID: 11197074
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction.
Okabe H; Yano I; Hashimoto Y; Saito H; Inui K
J Pharm Pharmacol; 2002 Jan; 54(1):65-70. PubMed ID: 11829131
[TBL] [Abstract][Full Text] [Related]
3. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
[TBL] [Abstract][Full Text] [Related]
4. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats.
Hashimoto Y; Sasa H; Shimomura M; Inui K
Pharm Res; 1998 Oct; 15(10):1609-13. PubMed ID: 9794505
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cyclosporin A and tacrolimus concentrations in whole blood between jejunal and ileal transplanted rats.
Ogino Y; Kobayashi E; Fujimura A
J Pharm Pharmacol; 1999 Jul; 51(7):811-5. PubMed ID: 10467956
[TBL] [Abstract][Full Text] [Related]
6. Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up.
Carcas-Sansuán AJ; Hierro L; Almeida-Paulo GN; Frauca E; Tong HY; Díaz C; Piñana E; Frías-Iniesta J; Jara P
Liver Transpl; 2013 Oct; 19(10):1151-8. PubMed ID: 23894093
[TBL] [Abstract][Full Text] [Related]
7. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers.
Hebert MF; Fisher RM; Marsh CL; Dressler D; Bekersky I
J Clin Pharmacol; 1999 Jan; 39(1):91-6. PubMed ID: 9987705
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic changes of intravenous tacrolimus in rats with uranyl nitrate-induced acute renal failure.
Son IJ; Moon YJ; Lee MG; Sohn YT
Res Commun Mol Pathol Pharmacol; 2000; 108(5-6):359-68. PubMed ID: 11958289
[TBL] [Abstract][Full Text] [Related]
9. The colon displays an absorptive capacity of tacrolimus.
Nishi K; Ishii T; Wada M; Amae S; Sano N; Nio M; Hayashi Y
Transplant Proc; 2004 Mar; 36(2):364-6. PubMed ID: 15050160
[TBL] [Abstract][Full Text] [Related]
10. Increased bioavailability of tacrolimus after rectal administration in rats.
Sakai M; Hobara N; Hokama N; Kameya H; Ohshiro S; Sakanashi M; Saitoh H
Biol Pharm Bull; 2004 Sep; 27(9):1480-2. PubMed ID: 15340245
[TBL] [Abstract][Full Text] [Related]
11. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
Arima H; Yunomae K; Hirayama F; Uekama K
J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
[TBL] [Abstract][Full Text] [Related]
12. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus.
Shimomura M; Masuda S; Saito H; Sakamoto S; Uemoto S; Tanaka K; Inui K
J Surg Res; 2002 Apr; 103(2):215-22. PubMed ID: 11922737
[TBL] [Abstract][Full Text] [Related]
13. No effect of water deprivation for 48 hours on the pharmacokiinetics of intravenous tacrolimus in rats.
Son IJ; Moon YJ; Lee MG; Sohn YT
Res Commun Mol Pathol Pharmacol; 2000; 107(3-4):279-89. PubMed ID: 11484882
[TBL] [Abstract][Full Text] [Related]
14. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
15. Hepatic extraction of tacrolimus in rats with experimental liver diseases.
Sasa H; Hashimoto Y; Shimizu T; Inui K
Biol Pharm Bull; 1998 Jun; 21(6):610-4. PubMed ID: 9657047
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation.
Sobiak J; Resztak M; Głyda M; Szczepaniak P; Chrzanowska M
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):331-8. PubMed ID: 25663618
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients.
Jacobson P; Ng J; Ratanatharathorn V; Uberti J; Brundage RC
Bone Marrow Transplant; 2001 Oct; 28(8):753-8. PubMed ID: 11781626
[TBL] [Abstract][Full Text] [Related]
18. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects.
Möller A; Iwasaki K; Kawamura A; Teramura Y; Shiraga T; Hata T; Schäfer A; Undre NA
Drug Metab Dispos; 1999 Jun; 27(6):633-6. PubMed ID: 10348790
[TBL] [Abstract][Full Text] [Related]
19. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug.
Nassar T; Rom A; Nyska A; Benita S
J Control Release; 2009 Jan; 133(1):77-84. PubMed ID: 18822327
[TBL] [Abstract][Full Text] [Related]
20. HGF prevents tacrolimus (FK 506)-induced nephrotoxicity in SHR rats.
Takada S; Namiki M; Takahara S; Matsumiya K; Kondoh N; Kitamura M; Uchida K; Koga M; Jiang H; Kokado Y; Kameoka H; Miki T; Matsumoto K; Nakamura T; Okuyama A
Transplant Proc; 1996 Apr; 28(2):1089-90. PubMed ID: 8623236
[No Abstract] [Full Text] [Related]
[Next] [New Search]
